What retatrutide is
Retatrutide, developed by Eli Lilly, is a once-weekly injectable designed to activate three hormone receptors: GLP-1, GIP and glucagon. Semaglutide acts on one (GLP-1) and tirzepatide on two (GLP-1 and GIP). The glucagon component is being studied for its potential to increase energy expenditure and liver fat reduction.
Where the research stands
In a 48-week Phase 2 trial published in the New England Journal of Medicine in 2023, participants on the highest doses lost an average of about 24% of body weight. Larger Phase 3 trials (the TRIUMPH program) are evaluating its safety and effectiveness. Phase 2 results do not guarantee Phase 3 outcomes or approval.
Our position
- We do not offer, compound or source retatrutide
- We are following published trial data
- If it receives FDA approval, we will evaluate offering it where clinically appropriate
- Be cautious of anyone selling retatrutide today — it is not an approved drug
Why not wait?
Approval timelines are uncertain. Semaglutide and tirzepatide have substantial evidence behind them now, and progress you make today — on weight, blood pressure and blood sugar — carries forward whatever options emerge later.